The largest database of trusted experimental protocols

10 protocols using chondroitin sulphate a

1

Quantification of Glycosaminoglycans in Tissues

Check if the same lab product or an alternative is used in the 5 most similar protocols
Frozen tissues were first weighted before the incubation with acetone to remove the lipids. The samples were then dried and cut into small pieces before the pronase treatment (15 mg pronase per hemisphere, (Roche, cat. no. 11459643001) in 0.1 M Trizma hydrochloride (Sigma-Aldrich, cat. no. T3253), 10mM calcium acetate (Millipore, cat. no. 567418), pH 7.8. Samples were homogenized with Potter Elvehjem tissue homogenizer in the pronase solution. Residual protein fragments were precipitated with trichloroacetic acid (Sigma-Aldrich, cat. no. T6399). The supernatant, which contains the GAGs, was collected and stored on ice. The solution was then neutralised with 1 M Na2CO3 (Sigma-Aldrich, cat. no. S7795) to pH 7.0, and the GAGs were recovered by ethanol precipitation. The isolated GAGs were redissolved in 0.3 ml of deionised water. The GAG concentration was quantified using cetylpyridium chloride (CPC) turbidimetry. Standard curve was prepared from 1µg/µl of Chondroitin sulphate A (Sigma-Aldrich, cat. no. C9819)31 . Briefly, the diluted sample was mixed with 0.2% (w/v) CPC and with 133 mM MgCl2 (Sigma-Aldrich, cat. no. M2670) in ratio 1:1. Absorbance was measured at 405 nm using plate reader spectrophotometer (FLUOstar® Omega, BMG LABTECH). Each sample was carried out in three different dilutions and each dilution was carried out in duplicate.
+ Open protocol
+ Expand
2

Purification and Characterization of ps20 Protein

Check if the same lab product or an alternative is used in the 5 most similar protocols
Using an Aktӓ-purifier FPLC system (GE Healthcare). 5 ml of 293T-ps20 CM was absorbed to a 1 ml HiTrap™ heparin-coated column (GE Healthcare) followed by 5 CV of washing with 50 mM Tris–HCl buffer (pH 7.5). A 0–0.5 M NaCl gradient was then applied to the column over 10 CV while 0.5 ml fractions were collected. These were then subjected to WB with 1G7. Heparin binding plates (BD Biosciences) coated overnight with 25 μg/ml GAGs; heparin sulphate, chondroitin sulphate A, and chondroitin sulphate C (all Sigma Aldrich) and blocked in PBS with 1% BSA (w/v). rps20293F diluted in PBS was absorbed for 2 h prior to washing and detection with 1G7-HRP. 100 μl of tetramethylbenzidine ELISA substrate was added and absorbance at 450 nm was measured as described for the ps20 ELISA above. A baseline was established by binding of rps20293F to a BSA solid phase. For the cell binding assay 293T cells, pre-treated with sodium chlorate where indicated, were resuspended using PBS (Gibco) with 4 mM EDTA (Sigma Aldrich). 106 cells were incubated with rps20V5+/− heparin with agitation for 1 h. Cells were washed once with 1 ml PBS and resuspended in 50 μl tissue lysis buffer (Sigma). Samples were then subjected to WB as indicated.
+ Open protocol
+ Expand
3

Chondroitin Sulfate Phantom Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Two sets of phantoms containing GAG prepared from chondroitin sulphate A (Sigma-Aldrich, St. Louis, Missouri, USA) and phosphate-buffered saline with varying pH values and concentrations were prepared. For the pH set, the GAG concentration was fixed at 60 mM and pH was titrated to 5.8, 6.1, 6.4, 6.7, and 7.0. For the concentration phantom, we used various GAG concentrations (100, 80, 60, 40, and 20 mM) and titrated the pH to 7.0. The solution was then transferred to 15 mL tubes. These 10 tubes were put in a phantom holder filled with water.
+ Open protocol
+ Expand
4

GAG-binding affinity of rIxsS17

Check if the same lab product or an alternative is used in the 5 most similar protocols
Secondary structure modeling predicted at least one basic patch in IxsS17 comparative modeling structure. To test if the rIxsS17 basic patch is functional, rIxsS17 binding affinity of glycosaminoglycans (GAGs): heparin (Sigma-Aldrich, MO, USA), chondroitin sulphate A (Sigma-Aldrich), heparan sulphate (Galen Laboratory Supplies, North Haven, CT) and dermatan sulphate (Galen Laboratory Supplies) was done as previously described [48 (link)]. A GAG-binding microplate (Galen Laboratory Supplies) was coated with 200 μL of GAG at the concentration of 25 μg/mL in binding buffer (100 mM NaCl, 50 mM Na-acetate, 0.2% Tween, pH 7.2) and incubated overnight at room temperature. After washing with binding buffer, the plate was blocked with 250 μL of 1% bovine serum albumin in PBS for 1 h at 37°C. Thereafter, different concentrations of rIxsS17 (0, 1, 2, 5, 10 and 20 μg/mL) in 200μL of blocking buffer was added and incubated for 2 h at 37°C. After the wash, 200 μL of HRP-conjugated anti-histidine antibody (1:5,000 dilution) was added. Following by addition of 200 μL of 1-step Ultra TMB ELISA substrate (Thermo Scientific), 100 μL of hydrochloric acid (1N) was used to stop the reaction; and the OD450 nm was determined using a microplate reader (Biotek Synergy H1).
+ Open protocol
+ Expand
5

Chondroitin Sulfate A Binding Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ibidi μ‐Slide 0.2 channel slides were incubated with 100 μl chondroitin sulphate A (100 μg/ml; Sigma Aldrich) in 1× PBS overnight at 37°C. Channels were blocked with 1% (w/v) BSA–PBS for 1 h at room temperature and flushed with warm bicarbonate‐free RPMI. CS2 parasites panned against chondroitin sulphate A98 were synchronized to 15–20 hpi, drug treated for 5 h to 20–25 hpi and diluted to 3% parasitaemia and 1% haematocrit in bicarbonate‐free RPMI 1640. Cells were passaged through the channel at 100 μl/min for 10 min at 37°C. Unbound cells were washed from the channel at 100 μl/min for 10 min at 37°C. Bound cells were imaged by widefield microscopy using a Zeiss Cell Observer widefield fluorescence microscope and counted over 10 fields of view (281.28 × 178.14 μm each) using ImageJ.
+ Open protocol
+ Expand
6

Quantitative Chondroitin Sulfate Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
DMMB (dimethylenmethylblue, Sigma-Aldrich) specifically stains chondroitin sulphate. Ten microlitres of the respective eluted GAG sample or of a standard dilution series (1:10) of known concentrations of chondroitin sulphate A (Sigma-Aldrich), used for calibration, were mixed with 190 μL DMMB staining solution (10 mL 2 M NaCl, 1.5 g glycine solved in 490 mL H2O, pH 3.0 adjusted with HCl; 8 mg DMMB solved in 2.5 mL ethanol and added) and measured in an ELISA-reader (Multiscan Go, Thermo Fisher Scientific) at 520 nm. All measurements were performed in triplets.
+ Open protocol
+ Expand
7

Glycosaminoglycan Content Quantification

Check if the same lab product or an alternative is used in the 5 most similar protocols
Glycosaminoglycan (GAG) content was evaluated by the dimethylmethylene blue assay (DMMB) (Sigma, 341088). Chondroitin sulphate A (Sigma, C9819) was used to generate 6 standards, concentrations ranging from 0 to 50 µg/mL Chondroitin sulphate C (Sigma, C4384) was used to generate low and high Internal Quality Control (IQC) solutions, concentrations 15 and 35 µg/mL, respectively. Cartibeads were digested with proteinase K (1 mg/mL, Promega, V3021) in Tris-HCl buffer (50 mM, pH 8, Sigma), for 15 ± 2 h at 56 °C. The enzymatic digestion was stopped by incubation at 97 °C for 15 minutes. The resulting sample was diluted (1:5-1:10) in Tris-HCl buffer (50 mM, pH 8) for the assay. One hundred micro liters of standard, ICQ, or sample were read in triplicates with a spectrophotometer (λ = 525 nm) after 5 minutes reaction with 1 mL of DMMB working solution.
+ Open protocol
+ Expand
8

Recombinant Cytokines and Glycosaminoglycans

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant human cytokines used in this study (CCL1, CCL2, CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12α, CXCL12β, CXCL13, CXCL14, CXCL16, XCL1, CX3CL1, IL-1α, IL-1β, IL-6, IL-6Rα, IL-10, IL-12p70, IL-13, IL-17a, IL-18BP-Fc, IL-23, IL-27, IL-35, TNF-α, TNF-β, IFN-β, IFN-γ, IFN-λ1, IFN-ω) from PeproTech, and (IFN-α2 and IL-18) from Sino Biological, were reconstituted in DPBS 0.1% BSA at 10 μM, aliquoted and stored at −80° C. Heparin (# 2106), heparan sulfate from bovine kidney (# H7640), chondroitin sulphate A (# C9819) and chondroitin sulphate B (# C3788) were obtained from MilliporeSigma. Heparan sulfate from porcine mucosa (# AMS.GAG-HS01) and keratan sulfate (# AMS.CSR-NAKPS2-SHC-1) were purchased from ASMBIO. We assumed an average molecular weight of 30 kDa for heparan sulfate from porcine mucosa and 15 kDa for Heparin36 .
+ Open protocol
+ Expand
9

Cytokine and Glycosaminoglycan Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant human cytokines used in this study (CCL1, CCL2, CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12α, CXCL12β, CXCL13, CXCL14, CXCL16, XCL1, CX3CL1, IL-1α, IL-1β, IL-6, IL- 6Rα, IL-10, IL-12p70, IL-13, IL-17a, IL-18BP-Fc, IL-23, IL-27, IL-35, TNF-α, TNF-β, IFN-β, IFN-γ, IFN-λ1, IFN-ω) from PeproTech, and (IFN-α2 and IL-18) from Sino Biological, were reconstituted in DPBS 0.1% BSA at 10 µM, aliquoted and stored at −80° C. Heparin (# 2106), heparan sulfate from bovine kidney (# H7640), chondroitin sulphate A (# C9819) and chondroitin sulphate B (# C3788) were obtained from MilliporeSigma. Heparan sulfate from porcine mucosa (# AMS.GAG-HS01) and keratan sulfate (# AMS.CSR-NAKPS2-SHC-1) were purchased from ASMBIO. We assumed an average molecular weight of 30 kDa for heparan sulfate from porcine mucosa and 15 kDa for Heparin 36 .
+ Open protocol
+ Expand
10

Cytokine Reconstitution and Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols
Recombinant human CKs used in this study (CCL1, CCL2, CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12α, CXCL12β, CXCL13, CXCL14, CXCL16, XCL1, CX3CL1, IL-1α, IL-1β, IL-6, IL-6Rα, IL-10, IL-12p70, IL-13, IL-17a, IL-18BP-Fc, IL-23, IL-27, IL-35, TNF-α, TNF-β, IFN-β, IFN-γ, IFN-λ1, IFN-ω) from PeproTech, and (IFN-α2 and IL-18) from Sino Biological, were reconstituted in DPBS 0.1% BSA at 10 μM, aliquoted and stored at −80° C. Heparin (# 2106), heparan sulfate from bovine kidney (# H7640), chondroitin sulphate A (# C9819) and chondroitin sulphate B (# C3788) were obtained from MilliporeSigma. Heparan sulfate from porcine mucosa (# AMS.GAG-HS01) and keratan sulfate (# AMS.CSR-NAKPS2-SHC-1) were purchased from ASMBIO. We assumed an average molecular weight of 30 kDa for heparan sulfate from porcine mucosa and 15 kDa for Heparin (65 ).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!